NYSE
309.41USD
-9.09 (-2.85%)
We have scored 46 news catalysts on Cencora, Inc. (COR) over the past 12 months. The biggest single-day move next to one of them came Mar 10, 2026, when COR closed −2.7%: “INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AeroVironment, Inc. - AVAV”. Coverage across the window leans mixed (average ticker sentiment −0.05). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
59.6B
P/E
—
EPS
—
Beta
0.57
52W range
244.82-377.54
Day range
309.31–319.76
Open
318.36
Prev close
318.50
Volume
1.1M
Avg volume
1.5M
Dividend
2.40
IPO
1995-04-04
Analysts publish price targets on COR, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
6 analyst price targets from $330 to $430
as of 2026-09-13
The market is 8% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Cencora, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for COR: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
The price sits at the very bottom of the published model range, 8% below the median target, meaning the market has fully absorbed the lowered revenue guidance and refuses to pay for any recovery or margin upside.
What the disagreement turns on
Whether pharmaceutical distribution unit volumes can grow fast enough to offset the manufactured list price reductions and push revenue growth back toward 7% or higher, which the wired data can measure via segment revenue history but cannot confirm without pricing data.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
